Therefore, increasing prevalence of type 2 diabetes and obesity is one of the significant factors driving the the Glucagon-like Peptide 1 (GLP-1) market growth in the forecast period
The pump holds a measured amount of NovoLog
The arm is a suitable alternative when other sites become uncomfortable, develop lipohypertrophy (fatty lumps), or when patients prefer variety in their injection routine
#Saroglitazar #IndianPharma #HealthcareInnovation #DrugDiscovery #NAFLD #DiabetesCare #MakeInIndia #Bioinformatics To view or add a comment, sign in Sun Pharmaceutical Industries has officially entered the semaglutide race in India with two new brands: Noveltreat(weight management) Sematrinity (Type 2 diabetes) And the real game-changer
However, despite the promising outlook, several challenges impede the mainstream adoption of plant-based GLP-1 agonists
This article explains how Mounjaro works and possible reasons for its potential fatigue-related side effects